Who founded Tizona Therapeutics, Inc.?

Tizona Therapeutics, Inc. was founded by Vijay K. Kuchroo, Drew Pardoll, Dario Vignali, Jedd Wolchok.

Who are Tizona Therapeutics, Inc.'s investors?

Tizona Therapeutics, Inc.'s investors include Canaan Partners, MPM BioImpact, Abingworth, Gilead Sciences, Astellas Venture Management LLC, Lightstone Ventures.

Tizona Therapeutics, Inc.

6 known investors

Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse. The company has advanced two internally generated immunotherapies into clinical trials and maintains a strategic alliance with Gilead Sciences.

AI & Machine Learning Biotech Healthtech

Founders & leadership

Vijay K. KuchrooScientific Co-Founder & Advisory Board Member

Drew PardollScientific Co-Founder & Advisory Board Member

Dario VignaliScientific Co-Founder & Advisory Board Member

Jedd WolchokScientific Co-Founder & Advisory Board Member

Christine O'BrienChief Executive Officer & Board Member

Courtney BeersChief Scientific Officer

Robert Ilaria, Jr.Chief Medical Officer

Board

Dan SpiegelmanBoard Chair

Investors · 6

Canaan Partners✓ verifiedStamford · $500K – $20M

MPM BioImpact✓ verifiedBoston · $1M – $15M

Abingworth✓ verifiedLondon · $15M – $30M

Gilead Sciences✓ verifiedFoster City

Astellas Venture Management LLCSouth San Francisco · $200K – $5M

Lightstone VenturesPortola Valley

Competitors · 3

by search overlap

Transcode Therapeutics17 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.

Solu15 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Sionnatx14 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.

Companies competing with Tizona Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers - BioSpacebiospace.com · Jun 2020

Bay Area's Tizona Therapeutics Emerges from Stealth Mode with $70 Million Total in Financing - BioSpacebiospace.com · Mar 2016

Tizona Therapeutics Closes $43M Series B Funding - FinSMEsfinsmes.com · Mar 2016

Frequently asked questions

What does Tizona Therapeutics, Inc. do?: Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse. The company has advanced two internally generated immunotherapies into clinical trials and maintains a strategic alliance with Gilead Sciences.
Who founded Tizona Therapeutics, Inc.?: Tizona Therapeutics, Inc. was founded by Vijay K. Kuchroo, Drew Pardoll, Dario Vignali, Jedd Wolchok.
Who are Tizona Therapeutics, Inc.'s investors?: Tizona Therapeutics, Inc.'s investors include Canaan Partners, MPM BioImpact, Abingworth, Gilead Sciences, Astellas Venture Management LLC, Lightstone Ventures.